INDIANAPOLIS — Eli Lilly announced Monday that one of its drugs has the potential to be a treatment for hospitalized COVID-19 patients.
As part of their "Adaptive COVID-19 Treatment Trial," Lilly and another pharmaceutical company called Incyte have been studying the drug baricitinib, a drug that commonly treats rheumatoid arthritis.
During phase three of studying baricitinib, Lilly found the emerging data to be "statistically significant."
"Recovery was defined as the participant being well enough for hospital discharge, meaning the participant either no longer required supplemental oxygen or ongoing medical care in the hospital, or was no longer hospitalized at Day 29," Lilly's report read.
The Indianapolis-based company plans to discuss a potential emergency use authorization for baricitinib as a treatment of hospitalized patients with COVID-19 with the U.S. Food and Drug Administration.
"If authorized for use, Lilly will propose that baricitinib be available through commercial channels and will work with hospitals and governments to ensure patient access," Lilly's report read.